Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma

Julius C Enßle; Julia Campe; Amelie Schwenger; Eliza Wiercinska; Helen Hellstern; Ralf Dürrwald; Michael A Rieger; Sebastian Wolf; Olivier Ballo; Björn Steffen; Hubert Serve; Halvard Bonig; Holger F Rabenau; Marek Widera; Sandra Ciesek; Ivana von Metzler; Evelyn Ullrich

doi:10.1182/blood.2021013429

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma

Blood. 2022 Jan 6;139(1):137-142. doi: 10.1182/blood.2021013429.

Authors

Julius C Enßle^{1

2

3

4}, Julia Campe^{2

5

6}, Amelie Schwenger^{2

5

6}, Eliza Wiercinska^{7

8}, Helen Hellstern^{7

8}, Ralf Dürrwald⁹, Michael A Rieger^{1

2

3

4}, Sebastian Wolf^{1

2

3

4}, Olivier Ballo¹, Björn Steffen¹, Hubert Serve^{1

2

3

4}, Halvard Bonig^{7

8}, Holger F Rabenau¹⁰, Marek Widera¹⁰, Sandra Ciesek^{10

11}, Ivana von Metzler^{1

2

3

4}, Evelyn Ullrich^{2

3

4

5

6}

Affiliations

¹ Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
² Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.
³ German Cancer Consortium (DKTK), Heidelberg, Germany.
⁴ German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁵ Experimental Immunology, Department for Children and Adolescents Medicine, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
⁶ Division of Pediatric Stem Cell Transplantation and Immunology, Department for Children and Adolescents Medicine, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
⁷ Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt am Main, Germany.
⁸ German Red Cross Blood Service BaWüHe, Frankfurt am Main, Germany.
⁹ Robert Koch-Institut, Berlin, Germany.
¹⁰ Insitute for Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; and.
¹¹ German Centre for Infection Research, External partner site, Frankfurt am Main, Germany.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

BNT162 Vaccine / pharmacology
BNT162 Vaccine / therapeutic use*
COVID-19 / immunology
COVID-19 / prevention & control*
Humans
Immunity, Cellular
Multiple Myeloma / complications*
Multiple Myeloma / immunology
SARS-CoV-2 / immunology
T-Lymphocytes / immunology*

Substances

BNT162 Vaccine